Patents by Inventor Brian Horsburgh

Brian Horsburgh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250049915
    Abstract: The present disclosure relates to nanoparticulate vaccine adjuvants, and to vaccine compositions which contain nanoparticulate vaccine adjuvants; to methods of preparing such adjuvants and compositions; and to methods of using such compositions and adjuvants for vaccination. The vaccine adjuvants disclosed herein are effective for enhancing the immune response to vaccination.
    Type: Application
    Filed: October 11, 2022
    Publication date: February 13, 2025
    Applicant: NewImmune II, LLC
    Inventors: Brian HORSBURGH, Mark David MOODY
  • Publication number: 20240335383
    Abstract: The present disclosure relates to nanoparticles and nanoparticulate compositions; methods of preparing such nanoparticles and nanoparticulate compositions; and associated methods of medical treatment and uses of such nanoparticles and nanoparticulate compositions for medical treatment, including the use of such nanoparticles for the manufacture of medicaments for medical treatment.
    Type: Application
    Filed: October 11, 2022
    Publication date: October 10, 2024
    Applicant: NewImmune II, LLC
    Inventors: Brian HORSBURGH, Mark David MOODY
  • Publication number: 20240335532
    Abstract: The present disclosure relates to nanoparticulate vaccine adjuvants, and to vaccine compositions which contain nanoparticulate vaccine adjuvants; to methods of preparing such adjuvants and compositions; and to methods of using such compositions and adjuvants for vaccination. The vaccine adjuvants disclosed herein are effective for enhancing the immune response to vaccination.
    Type: Application
    Filed: October 11, 2022
    Publication date: October 10, 2024
    Applicants: NewImmune II, LLC, IMMUNOVA THERAPEUTICS LTD
    Inventors: Brian HORSBURGH, Mark David MOODY
  • Publication number: 20210015758
    Abstract: Nanoparticulate compositions are disclosed. The nanoparticulate compositions typically include at least one, preferably two or more, active agent(s), one of which is an immunomodulatory compound, loaded into, attached to the surface of and/or enclosed within a delivery vehicle. The delivery vehicles can be nanolipogels including a polymeric core and a lipid shell or a biodegradable polymeric nanoparticle such as a PLGA nanoparticle. Typically, at least one of the active agents is an immunomodulator that increases an immune stimulatory response or decreases an immune suppressive response. In some embodiments, the particle includes both an immunomodulator that increases an immune stimulatory response and an immunomodulator that decreases an immune suppressive response. The particles can be decorated with a targeting moiety that improves delivery to a target cell. Methods of using the compositions to enhance an immune response and treat diseases such as cancer are also disclosed.
    Type: Application
    Filed: August 6, 2020
    Publication date: January 21, 2021
    Inventors: Tarek Fahmy, Brian Horsburgh
  • Patent number: 10751291
    Abstract: Nanoparticulate compositions are disclosed. The nanoparticulate compositions typically include at least one, preferably two or more, active agent(s), one of which is an immunomodulatory compound, loaded into, attached to the surface of and/or enclosed within a delivery vehicle. The delivery vehicles can be nanolipogels including a polymeric core and a lipid shell or a biodegradable polymeric nanoparticle such as a PLGA nanoparticle. Typically, at least one of the active agents is an immunomodulator that increases an immune stimulatory response or decreases an immune suppressive response. In some embodiments, the particle includes both an immunomodulator that increases an immune stimulatory response and an immunomodulator that decreases an immune suppressive response. The particles can be decorated with a targeting moiety that improves delivery to a target cell. Methods of using the compositions to enhance an immune response and treat diseases such as cancer are also disclosed.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: August 25, 2020
    Assignee: Yale University
    Inventors: Tarek Fahmy, Brian Horsburgh
  • Publication number: 20180200196
    Abstract: Nanoparticulate compositions are disclosed. The nanoparticulate compositions typically include at least one, preferably two or more, active agent(s), one of which is an immunomodulatory compound, loaded into, attached to the surface of and/or enclosed within a delivery vehicle. The delivery vehicles can be nanolipogels including a polymeric core and a lipid shell or a biodegradable polymeric nanoparticle such as a PLGA nanoparticle. Typically, at least one of the active agents is an immunomodulator that increases an immune stimulatory response or decreases an immune suppressive response. In some embodiments, the particle includes both an immunomodulator that increases an immune stimulatory response and an immunomodulator that decreases an immune suppressive response. The particles can be decorated with a targeting moiety that improves delivery to a target cell. Methods of using the compositions to enhance an immune response and treat diseases such as cancer are also disclosed.
    Type: Application
    Filed: January 3, 2018
    Publication date: July 19, 2018
    Inventors: Tarek Fahmy, Brian Horsburgh
  • Patent number: 9884026
    Abstract: Nanoparticulate compositions are disclosed. The nanoparticulate compositions typically include at least one, preferably two or more, active agent(s), one of which is an immunomodulatory compound, loaded into, attached to the surface of and/or enclosed within a delivery vehicle. The delivery vehicles can be nanolipogels including a polymeric core and a lipid shell or a biodegradable polymeric nanoparticle such as a PLGA nanoparticle. Typically, at least one of the active agents is an immunomodulator that increases an immune stimulatory response or decreases an immune suppressive response. In some embodiments, the particle includes both an immunomodulator that increases an immune stimulatory response and an immunomodulator that decreases an immune suppressive response. The particles can be decorated with a targeting moiety that improves delivery to a target cell. Methods of using the compositions to enhance an immune response and treat diseases such as cancer are also disclosed.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: February 6, 2018
    Assignee: YALE UNIVERSITY
    Inventors: Tarek Fahmy, Brian Horsburgh
  • Publication number: 20040171569
    Abstract: The invention provides artificial chromosome constructs containing foreign nucleic acid sequences, such as viral nucleic acid sequences, and methods of using these artificial chromosome constructs for therapy and recombinant virus production.
    Type: Application
    Filed: November 4, 2003
    Publication date: September 2, 2004
    Inventors: Brian Horsburgh, Dong Qiang, Francis Tufaro, Jeffrey Ostrove
  • Publication number: 20040166092
    Abstract: The invention provides viral vectors and charged molecules for use in gene therapy.
    Type: Application
    Filed: February 26, 2004
    Publication date: August 26, 2004
    Inventors: Francis Tufaro, Sonia Yeung, Brian Horsburgh
  • Patent number: 6642207
    Abstract: The invention provides artificial chromosome constructs containing foreign nucleic acid sequences, such as viral nucleic acid sequences, and methods of using these artificial chromosome constructs for therapy and recombinant virus production.
    Type: Grant
    Filed: August 3, 2001
    Date of Patent: November 4, 2003
    Assignee: MediGene, Inc.
    Inventors: Brian Horsburgh, Dong Qiang, Francis Tufaro, Jeffery Ostrove
  • Patent number: 6277621
    Abstract: The invention provides artificial chromosome constructs containing foreign nucleic acid sequences, such as viral nucleic acid sequences, and methods of using these artificial chromosome constructs for therapy and recombinant virus production.
    Type: Grant
    Filed: February 26, 1998
    Date of Patent: August 21, 2001
    Assignee: MediGene, Inc.
    Inventors: Brian Horsburgh, Dong Qiang, Francis Tufaro, Jeffrey Ostrove